Gene Therapy & Genetic Medicine

Big pharma M&A is aggressively restocking gene and cell therapy pipelines

The acquisition wave in genetic medicine intensified dramatically, with Novartis acquiring Myricx Bio for $1.5B (signals [0],[1]) just months after Eli Lilly paid up to $7B for Kelonia Therapeutics ([46]) and UCB acquired Candid Therapeutics for $2.2B ([34]). Lilly's deal was explicitly framed as a hedge against GLP-1 revenue concentration ([46]), and PitchBook's senior biotech analyst defended the Kelonia premium on the durability of its iGPS® in vivo gene placement technology ([44]). This pattern — large upfront payments for platform-level gene delivery assets — signals that pharma is prioritizing next-generation modalities over incremental pipeline additions, and is willing to pay multiples far above last-known private valuations (Kelonia's last round was a $104M post-money in 2022).

Kelonia's iGPS® platform — which uses engineered lentiviral particles to reprogram T-cells inside the body without ex vivo manufacturing — commanded a $7B acquisition price from Eli Lilly ([46]), validating the in vivo CAR-T paradigm over complex cell manufacturing. SonoThera's $125M Series B ([3],[5]) drew a syndicate spanning J&J Innovation, Leaps by Bayer, RA Capital, Illumina Ventures, UCB Ventures, and Alexandria Venture Investments, reflecting cross-sector conviction in ultrasound-mediated in vivo delivery as a nonviral alternative ([7]). The breadth of strategic and financial investors across these rounds suggests in vivo delivery is no longer a speculative bet but an emerging standard.

Why it matters · Companies that can demonstrate scalable, durable in vivo delivery — avoiding the cost and complexity of ex vivo manufacturing — are likely to be the next acquisition targets.

SonoThera's $125M Series B ([3],[5]), backed by Leaps by Bayer, J&J Innovation, and Otsuka Pharmaceutical, is the clearest signal that nonviral delivery — specifically ultrasound-mediated gene delivery — is moving from research curiosity to institutionally validated platform. Commentators explicitly framed the round as evidence that nonviral approaches are reaching a "critical validation inflection point" by sidestepping the immune challenges of viral vectors ([4],[7]).

Why it matters · If nonviral delivery platforms demonstrate clinical proof-of-concept, they could displace viral vector manufacturing as the dominant gene therapy modality, reshaping the CDO landscape.

Chan Zuckerberg Initiative deployed $500M across two funding tranches ([6],[30]) into the CZ Biohub's hierarchical biology world-model program — proteins → cells → whole systems ([11]) — while recruiting the former Head of Science from Evolutionary Scale ([10]). ESM Fold 2 folded 1.1 billion proteins and produced nanomolar antibody binders as an emergent capability ([16]), and the ESM Atlas has now mapped 6.8 billion proteins ([29]). General Catalyst co-seeded both Vevo Therapeutics and Tahoe Therapeutics at $12.25M each ([25],[26]), backing AI-native approaches that integrate in vivo data with single-cell techniques for cancer drug discovery. CZI's Cell by Gene open platform has become a foundational corpus for transcriptomic AI models ([15]).

Why it matters · Investors who back the data infrastructure layer — cell atlases, protein language models, in vivo data atlases — may capture disproportionate value as genetic medicine shifts from discovery to engineering.

CHOP's delivery of the first personalized CRISPR therapeutic to a child for a rare metabolic disease ([14]) was cited as a landmark for clinical translation of gene editing. CZI is actively partnering with Jennifer Doudna on a CRISPR Cures program at UCSF ([17]), positioning philanthropic capital as a bridge between academic breakthroughs and commercial deployment.

Why it matters · As personalized CRISPR therapies demonstrate clinical safety, the regulatory and reimbursement frameworks they establish will unlock a broader market for bespoke gene editing medicines.